Maraviroc-containing HIV PrEP regimens safe, well tolerated

August 23, 2017

(HealthDay)—Maraviroc (MVC)-containing HIV pre-exposure prophylaxis (PrEP) regimens are well tolerated for preventing HIV infection in uninfected women, according to a study published online Aug. 22 in the Annals of Internal Medicine.

Roy M. Gulick, M.D., M.P.H., from Weill Cornell Medicine in New York City, and colleagues conducted a phase 2 study of four antiretroviral regimens used as PrEP in 12 clinical research sites among HIV-uninfected women reporting condom-less vaginal or with at least one man with HIV or unknown serostatus. Participants received MVC only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

Eighty-five percent of the 188 participants completed follow-up; 19 percent discontinued their regimen prematurely. The researchers observed no difference among regimens in the number discontinuing and the time to discontinuation. Five MVC, 13 MVC-FTC, nine MVC-TDF, and eight TDF-FTC participants had grade 3 or 4 adverse events; the rates did not differ among regimens. The MVC-TDF group had one death by suicide, which was judged not to be related to study drugs. Sixty percent of the 126 available plasma samples at week 48 showed detectable drug concentrations. There were no new HIV infections.

"Maraviroc-containing PrEP regimens were safe and well tolerated compared with TDF-FTC in U.S. women," the authors write. "Maraviroc-containing PrEP for women may warrant further study."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Maraviroc-containing regimens safe, tolerable when taken for HIV prevention

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Maraviroc-containing regimens safe, tolerable when taken for HIV prevention

February 24, 2016
Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk ...

Protection against HSV-2 is added benefit of tenofovir

July 2, 2014
(HealthDay)—Tenofovir for HIV-1 preexposure prophylaxis (PrEP) provides the added benefit of protection against herpes simplex virus type 2 (HSV-2) acquisition, according to a study published in the July 1 issue of the ...

Small changes in eGFR with TDF preexposure prophylaxis

December 23, 2014
(HealthDay)—For HIV-1-uninfected members of serodiscordant couples, tenofovir disoproxil fumarate (TDF) used as preexposure prophylaxis (PrEP) is associated with a small decrease in estimated glomerular filtration rate ...

Patient infected with HIV despite long-term adherence to PrEP

February 2, 2017
(HealthDay)—In a letter to the editor published in the Feb. 2 issue of the New England Journal of Medicine, authors present the case of a Canadian man infected with HIV despite long-term adherence to pre-exposure prophylaxis ...

International study finds high levels of adherence to use of rectal microbicide gel

October 20, 2016
Participants enrolled in a rectal microbicide study were just as likely to follow through using an anti-HIV gel with anal sex as they were to using daily oral pre-exposure prophylaxis (PrEP), according to adherence results ...

Preventive HIV treatment shown effective at health clinics

November 17, 2015
(HealthDay)—Real-world application of pre-exposure prophylaxis (PrEP) medications appears to be effective for the prevention of HIV, but racial discrepancies exist, new research suggests. The studies appear online Nov. ...

Recommended for you

Study shows how HIV is shielded from immune attack

July 10, 2018
Scientists from UNSW Sydney and the UK have discovered that the human immunodeficiency virus (HIV) hijacks a small molecule from the host cell to protect itself from being destroyed by the host's immune system.

Out-of-pocket costs put HIV prevention drug out of reach for many at risk

July 4, 2018
Public health officials are expanding efforts to get the HIV prevention pill into the hands of those at risk, in a nationwide effort to curb infections. But the officials are hitting roadblocks—the drug's price tag, which ...

New simulation tool predicts how well HIV-prophylaxis will work

June 14, 2018
A new mathematical simulation approach predicts the efficacy of pre- and post-exposure prophylaxis (PrEP) medications, which help prevent HIV infection. The framework, presented in PLOS Computational Biology by Sulav Duwal ...

Many at risk for HIV despite lifesaving pill

June 11, 2018
Multiple barriers may stop high-risk individuals from accessing an HIV drug that can reduce the subsequent risk of infection, according to a new University of Michigan study.

Active HIV in large white blood cells may drive cognitive impairment in infected mice

June 7, 2018
Macrophages, large white blood cells that engulf and destroy potential pathogens, harbor active viral reserves that appear to play a key role in impaired learning and memory in mice infected with a rodent version of HIV. ...

HIV vaccine elicits antibodies in animals that neutralize dozens of HIV strains

June 4, 2018
An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world. The findings were reported ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.